Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer

(E-pub Ahead of Print)

Author(s): Mehdi Rajabi, Mary Adeyeye, Shaker A. Mousa*.

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer


Targeting angiogenesis in the microenvironment of a tumor can enable suppression of tumor angiogenesis and delivery of anticancer drugs into the tumor. Anti-angiogenesis targeted delivery systems utilizing passive targeting such as enhanced permeability and retention (EPR) and specific receptor-mediated targeting (active targeting) should result in tumor-specific targeting. One targeted anti-angiogenesis approach uses peptides conjugated to nanoparticles, which can be loaded with anticancer agents. Anti-angiogenesis agents can suppress tumor angiogenesis and thereby affect tumor growth progression (tumor growth arrest), which may be further reduced with the target-delivered anticancer agent. This review provides an update of tumor vascular targeting for therapeutic and diagnostic applications, with conventional or long-circulating nanoparticles decorated with peptides that target neovascularization (anti-angiogenesis) in the tumor microenvironment.

Keywords: angiogenesis, anti-angiogenesis, anticancer, chemotherapy, passive targeting, active targeting, peptide, nanoparticles, cancer therapy, diagnosis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867326666190620100800
Price: $95

Article Metrics

PDF: 2